MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, MAZE had $52,232K increase in cash & cash equivalents over the period. -$24,710K in free cash flow.

Cash Flow Overview

Change in Cash
$52,232K
Free Cash flow
-$24,710K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net (loss) income
-30,087 -66,465
Depreciation
571 1,333
Stock-based compensation expense
3,864 6,463
Non-cash lease expense
787 1,543
Accretion of discounts on marketable securities
278 -
Other items, net
0 21
Prepaid expenses and other current assets
758 1,750
Other assets
-356 -18
Accounts payable
-748 1,846
Accrued expenses and other liabilities
2,476 -957
Operating lease liabilities
-825 -1,620
Net cash (used in) provided by operating activities
-24,642 -59,568
Purchases of marketable securities
66,815 -
Purchases of property and equipment
68 692
Net cash used in investing activities
-66,883 -692
Proceeds from initial public offering, net of offering costs paid
0 127,752
Proceeds from private placement, net of offering costs paid
141,748 -
Proceeds from exercise of stock option awards, net of repurchases
2,009 126
Proceeds from issuance of common stock under the 2025 employee stock purchase plan
0 612
Payment of success fee derivative
0 500
Net cash provided by financing activities
143,757 127,990
Net increase in cash, cash equivalents, and restricted cash
52,232 67,730
Cash and cash equivalents at beginning of period
197,900 -
Cash and cash equivalents at end of period
317,862 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics, Inc. (MAZE)